Resum
We hereby describe the satisfactory evolution of rituximab treatment in two patients with Wegener's granulomatosis (WG). Rituximab was indicated for refractoriness to standard treatment in one case and life-threatening myelotoxicity due to alkylating agents in the other. A brief review of previous experience with the use of rituximab in the treatment of WG is presented. © Oristrell et al.; Licensee Bentham Open.
Idioma original | Anglès |
---|---|
Pàgines (de-a) | 94-99 |
Revista | Open Respiratory Medicine Journal |
Volum | 3 |
DOIs | |
Estat de la publicació | Publicada - 1 de des. 2009 |